TMO

Thermo Fisher Scientific Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 699.44 Healthcare - Medical - Diagnostics & ResearchREDUCE ZONE

ACTIONABLEMethodology gates passed

Position levels

Currenttoday

USD 699.44

Buy <=wait / entry

USD 576.67

Trim >=take some off

USD 690.00

Thesis breakThe thesis would be invalidated by a material cut to 2026 or 2027 organic revenu...

Scenario-weighted conviction

	Probability	Score	Contribution
Bull case	26%	100 / 100	26.0
Base case	53%	62 / 100	32.9
Bear case	21%	10 / 100	2.1
Weighted conviction			61 / 100 - OPPORTUNISTIC BUY

Top risks

M&A divestiture of microbiology business to Astorg for $1.075 billion
Q2 2026 revenue +10% to $11.99B and adjusted EPS +13% to $6.03 with raised full-year guidance to $47.4-48.1B revenue and $24.93-25.33 adjusted EPS
Launch of high-impact products including Orbitrap Astral Zoom mass spectrometer, Krios 5 Cryo-TEM, Vulcan Automated Lab, and 5L DynaDrive Bioreactor

Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.